Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

502 results about "Endocytosis" patented technology

Endocytosis is a cellular process in which substances are brought into the cell. The material to be internalized is surrounded by an area of cell membrane, which then buds off inside the cell to form a vesicle containing the ingested material. Endocytosis includes pinocytosis (cell drinking) and phagocytosis (cell eating). It is a form of active transport.

Remote detection of substance delivery to cells

InactiveUS20050112065A1Highly preventive effectIncreasing effect on proton relaxivityDiagnostics using lightDispersion deliveryLipid formationElectrochemical gradient
The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring.
Owner:SUTTER WEST BAY HOSPITALS

Fusion proteins

A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
Owner:HEALTH PROTECTION AGENCY +1

Method of targeted gene delivery using viral vectors

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
Owner:CALIFORNIA INST OF TECH

Cell-penetrating peptide modified nanoparticle and its preparation method

InactiveCN102988295AIncreased cellular uptakeImprove biostability in vivoPowder deliveryPeptide/protein ingredientsSide effectWhole body
The invention belongs to the medicinal preparation field, relates to a cell-penetrating peptide modified nanoparticle, and concretely relates to a nanoparticle delivery system for oral polypeptide and protein medicines, and its preparation method. The medicine delivery system is composed of the nanoparticle, cell-penetrating peptides modified on the surface of the nanoparticle, and the polypeptide protein medicines sealed by the nanoparticle, wherein the average particle size range of the medicine delivery system is 10-500nm. The cell-penetrating peptide modified nanoparticle and glucosaminoglycan having electronegative cell surfaces undergo electric property attraction and then undergo endocytosis, so the cell-penetrating peptide modified nanoparticle and the glucosaminoglycan are integrally taken into cells; and the cell-penetrating peptide modified nanoparticle has an alimentary canal mucous membrane penetrating capability after the cell-penetrating peptide modified nanoparticle is orally taken, and can deliver the polypeptide protein medicines carried by the cell-penetrating peptide modified nanoparticle to the whole body for blood circulation, so the oral biological utilization degree of the medicines are improved. The cell-penetrating peptide modified nanoparticle has the advantages of improvement of the stability of polypeptide and protein medicines in the alimentary canal, reduction of the application amount of cell-penetrating peptides, and reduction of possible toxic side effects caused by the cell-penetrating peptides.
Owner:FUDAN UNIV

Specific target polypeptide self-assembled nano-carrier, drug-carrying nanoparticle and preparation method

The invention relates to the technical field of biology and in particular relates to a specific target polypeptide self-assembled nanoparticle. The nanoparticle is prepared from a hydrophobic anti-tumor drug with a therapeutic dosage and an amphipathic polypeptide which covers the periphery of the hydrophobic anti-tumor drug through a self-assembling manner, wherein the amphipathic polypeptide is a target peptide which can be used for specifically targeting a epidermal growth factor receptor of a tumor cell; a terminal N of the target peptide is coupled with a hydrophobic functional molecule. After the nanoparticle targets the tumor cell, the target peptide is exposed; the nanoparticle targets the tumor cell and enters the tumor cell through receptor-mediated endocytosis, and the drug is released to inhibit DNA (Deoxyribonucleic Acid) synthesis and repairing; the nanoparticle has dual killing effects on the tumor cells and the growth of the tumor cell is inhibited. The amphipathic polypeptide does not generate a covalent bond in a self-assembling process and no reverse reaction is caused; the specific target polypeptide self-assembled nanoparticle is used for treating tumors and has the advantages of no toxin and good biocompatibility.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Supramolecule assembly of targeting-delivery anticancer adamplatin and preparation of supramolecule assembly

The invention discloses a supramolecule assembly of targeting-delivery anticancer adamplatin. The supramolecule assembly is a binary supramolecule assembly which is synthesized on the basis of cyclodextrin-decorated hyaluronic acid and adamplatin. A preparation method of the supramolecule assembly is characterized in that the cyclodextrin-decorated hyaluronic acid and the adamplatin are respectively synthesized, and through the strong non-covalent interaction of cyclodextrin and adamantine and the amphiphilic action of molecules, a supermolecule nano particle which takes the hydrophilic hyaluronic acid as a shell and the adamplatin as a core is formed. The supramolecule assembly disclosed by the invention has the advantages that the supramolecule assembly of the targeting-delivery anticancer adamplatin has a simple synthetic route, is low in preparation cost and high in productivity, and is suitable for amplification synthesis and practical production application; and through endocytosis in which a malignant cell surface hyaluronic acid receptor serves as a medium, the supramolecule assembly (HAP) is brought in cancer cells in a target manner, so that the protection of normal cells and the targeting selective killing of cancer cells are realized, the anti-cancer activity is obviously improved, and toxic and side effects are obviously reduced.
Owner:NANKAI UNIV

Exosome-encapsulated nano drug-loading system for tumor treatment and preparation thereof

ActiveCN108543074AIngestion behaviorExcellent killing effectOrganic active ingredientsInorganic non-active ingredientsExocytosisTumor targeting
The invention discloses an exosome-encapsulated nano drug-loading system for tumor treatment, and preparation thereof. The system is obtained by utilizing cell endocytosis of a drug-loading nanometermaterial and then exocytosis. The drug-loading nanometer material is loaded with an antitumor medicine including at least one of a chemotherapeutic, a medicine used for immunotherapy and a medicine used for modifying a tumor microenvironment. The composition, structure and the like of the key outer component biofilm encapsulating the nano drug-loading system are improved, and compared with the prior art, the exosome-encapsulated nano drug-loading system provides a novel route for biofilm-based biological processed nanoparticles. By utilization of the exosome-encapsulated nano drug-loading system, the composition and the structure of the exosome can be maintained greatly, and the obtained exosome-encapsulated nano drug-loading system has good stability and tumor targeting performance duringblood circulation. .
Owner:HUAZHONG UNIV OF SCI & TECH

Glutathione-modified chitosan copolymer serving as non-viral gene carrier material and preparation and application thereof

The invention discloses a glutathione-modified chitosan copolymer serving as a non-viral gene carrier material and preparation and application thereof, which belong to the fields of gene therapy and novel materials. A preparation method of the copolymer comprises the following steps of: (1) synthesizing an allyl-modified chitosan derivative; (2) synthesizing brush-like PEG (Polyethylene Glycol) polymer chains with different molecular weights through RAFT (Reversible Addition-Fragmentation Chain Transfer); (3) grafting the brush-like PEG onto a chitosan framework by adopting a free radical coupling method; and (4) linking glutathione to the chain end of the brush-like PEG by adopting an EDC (1-Ethyl-3-(3-Dimethyllaminopropyl) Carbodiimide hydrochloride)/NHS (N-hydroxysuccinimide) activation method to obtain a glutathione-modified chitosan copolymer carrier material. The glutathione-modified chitosan copolymer obtained by adopting the technology serves as the non-viral gene carrier material. By adopting the copolymer, the endocytosis function of a composite nanoparticle formed from the copolymer and DNA (Deoxyribonucleic Acid) can be remarkably enhanced, the releasing mechanism of DNA from a composite particle after cell entrance is improved, and the non-viral gene carrier material with a high transfection efficiency is further obtained.
Owner:NANKAI UNIV

Slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system, and preparation method thereof

The invention belongs to the field of biotechnology, and relates to a slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system, and a preparation method thereof. The slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system is prepared via self-assembly of a slightly acidic environment targeted polypeptide modified dendrimer encapsulated gene, wherein the surface of the dendrimer is rich of amino groups. According to the preparation method, a polypeptide of transmembrane helix protein C derived from bacteria visual purple is used for modifying a high molecular carrier, enrichment and adhesion onto cells is realized via a pH sensitive cell membrane insertion method, and entering into cells is realized via electrostatic adsorption guided endocytosis, so that untaking of tumor cells on drugs is improved, and toxic and side effects are reduced. According to the tumor targeted nano drug delivery system, cell membrane is taken as the target point, and the polypeptide is taken as the target head group in tumor slightly acidic environment, targeting and curing efficiency are high, the preparation method is simple and convenient, and tumor cell drugs, which are derived from human or animal, and is used for targeted therapy, can be prepared.
Owner:FUDAN UNIV

Functional albumin and preparation method of nano preparation of functional albumin

ActiveCN105288647AThe synthesis method is simpleChange isoelectric point to basicPowder deliveryOvalbuminExocytosisDrug release
The invention discloses functional albumin and a preparation method of a nano preparation of the functional albumin. The nano preparation of the functional albumin consists of the functional albumin, metal ions and a drug; the metal ions can simultaneously form coordination bonds with the functional albumin and the drug, and can form nanoparticles through induced self-assembly. The nano preparation, through an endocytosis mediated by an albumin receptor (SPARC) on the surface of tumor cells, can deliver the drug into the drug-resistant tumor cells, so as to effectively avoid the exocytosis effect of a p-gp pump on the drug, and then as the coordination bonds break in an acid tumor cell environment through a pH responsibility, the drug releases in cytoplast, enters cell nucleus and inlays in DNA so as to inhibit the synthesis of nucleic acid; and therefore, the growth of the tumor cells is inhibited. Through in vitro characterization, the nano preparation can achieve the relatively good pH responsibility; and through activity evaluation on a cellular level, the system is capable of effectively delivering the drug into the cells, so as to achieve relatively good pH responsive release.
Owner:CHINA PHARM UNIV

An antibody-coupled drug targeting on EGFR, a preparation method thereof, and uses thereof

The invention discloses an antibody coupling drug targeting on EGFR, a preparation method thereof and uses thereof. The antibody-conjugated drug targeting EGFR is named LR004-VC-MMAE consisting of anantibody, a cytotoxic drug and a linker, wherein the antibody drug conjugate has a structure represented by the formula I, wherein mAb is an LR004 monoclonal antibody, n=2-8. The novel antibody-conjugated drug LR004-VC-MMAE can not only target EGFR antigen, but also has strong cytotoxicity to tumor cells. Compared with LR004 itself, it did not affect the affinity, endocytosis and targeting of theantibody, and better retained its biological function. Compared to LR004, the antitumor effect of LR004-VC-MMAE antibody-conjugated drug is significantly improved, and the tumor disappeared. Comparedto LR004, LR004-VC-MMAE antibody-conjugated total antibody showed longer half-life, slower clearance rate, lower concentration of free MMAE in plasma, shorter half-life and faster clearance rate, which is conducive to reduce toxicity.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products